🔗 Share this article

While the United States continues making unprecedented changes to its vaccine schedules, one figure appears in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by questioning coronavirus shots during the global health crisis and has concentrated on alleged fatalities after COVID-19 vaccination in her short tenure at the Food and Drug Administration.

Proposed Shifts to Pediatric Vaccine Program

Agency leaders planned to announce major revisions to the pediatric vaccination calendar recently, aligning the US with the Danish immunization schedule, it is understood – a substantial departure that would place the US out of alignment with much of the world with little proof for benefit. The planned update has been pushed back until the new year.

Instead of the top vaccines chief, Tracy Beth Høeg is listed to present at the event. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth individual to head the center this year.

A Shift at the Agency

This interim role could signify a tighter collaboration between the pharmaceutical and vaccine branches as Dr. Høeg and Prasad solidify control at the regulatory agency – and it suggests a greater focus upon rolling back already-approved immunizations at the FDA.

Høeg has often pushed for ending specific childhood immunization guidelines in the US so as to align more in line with the Danish model, a society with nationalized medicine and a number of inhabitants about the population of Wisconsin’s.

In her initial public appearances, she has persisted in emphasizing on vaccines – traditionally the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Concerns Over Expertise

Dr. Høeg has no obvious background in pharmaceutical research, regulation or administrative roles, which has been standard for former directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the FDA chief and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for overseeing the CDER, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in leading a major agency. She has no expertise in drug approvals.”

Previous directors of the center would “understand regulatory frameworks and the science of drug development”, said a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that prior appointees who ran the center have had.”

The drug center has an enormous range of responsibilities at the agency, Woodcock emphasized.

“Everybody just focuses on the new drug program, but the generic drug division approves numerous generic medications. There’s a biologic copycat branch, OTC medication office and other areas, and each of these have to be managed,” she said. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

There is also, a substantial administrative aspect to the position, which oversees more than 5,000 staff members. “It’s a massive leadership role, if you execute it properly,” the former official said.

Agency Reaction and Controversial Initiatives

When asked about questions about Høeg’s credentials and whether this selection indicates increased cooperation among agency officials on vaccines, a spokesperson said that the “questions are based on inaccurate assumptions”.

“Her resume is consistent with the responsibilities of her position,” the spokesperson said, noting the time Dr. Høeg spent counseling the agency head on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg takes over the agency head's new expedited review system, a contentious one-day therapy clearance system that allegedly worried her preceding directors. “By what process are these drugs being selected for this voucher program? Who takes the decisions?” Howard questioned. “There is a lot of confidentiality happening at the regulatory body right now.”

Overall, he stated, “the FDA seems to be moving towards laxer rules of pharmaceuticals, except for shots.”

Public Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a clearer, if problematic, history, critics observe. She released a study using non-validated crowd-sourced reports to assess the incidence of heart inflammation following COVID-19 immunization. She advised the Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccines are pose a greater threat than they are.

Among her “wish list” for the new administration featured changing regulations for novel immunizations and halting “unnecessary” immunizations, she said after the election on a podcast. At the agency, Høeg has according to sources suggested preventing teenage boys from getting Covid vaccinations.

“She’s an all-around ideologue who commences with her conclusions and reverse-engineers to retrofit the data in a highly disingenuous, untruthful fashion,” Dr. Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with other skeptics, {like|